This is a zero-cost option on a new category for Evolus. The key catalyst is FDA approval timing and the subsequent commercial launch. Monitor for clinical/regulatory milestones and initial market reception in the U.S. The deal removes execution risk on the cost side but adds regulatory and commercial execution risk on the revenue side.
Price Chart
Executive Summary
Evolus entered into an exclusive license and distribution agreement with IBSA to develop and commercialize Profhilo, a market-leading injectable hyaluronic acid product for skin quality, in the United States. The deal requires no upfront or milestone payments from Evolus, uses a transfer-price model, and is not expected to impact the company's 2026 or 2028 financial guidance. This expands Evolus' aesthetic portfolio into the skin quality segment, a fast-growing and underpenetrated category in the U.S.
Key Financial Metrics
Key Facts
- Evolus and IBSA entered into an exclusive License, Supply and Distribution Agreement for Profhilo in the U.S. on July 7, 2026.
- Profhilo is the market-leading injectable for skin quality in Europe, with over 4.8 million treatments administered globally since 2015.
- The agreement requires no upfront payment or milestone payments from Evolus.
- Evolus is responsible for all U.S. development, clinical, and regulatory activities to support FDA approval.
- The initial term is 15 years from first FDA approval, with renewal options for successive 5-year terms.
- The agreement is not expected to impact Evolus' previously communicated 2026 revenue, operating expense, or operating profit outlook, nor its 2028 revenue or profitability targets.
- Minimum purchase requirements begin in the fourth year following commercial launch.
Financial Impact
No upfront or milestone payments. Economics structured through a transfer-price model designed to support gross margins consistent with Evolus' long-term financial framework. No impact on 2026 or 2028 financial guidance.
Risk Factors
- FDA approval is not guaranteed and the timeline is uncertain.
- U.S. skin quality injectable market is in early stages and may not develop as expected.
- Minimum purchase requirements starting in year 4 post-launch create downside risk if adoption is slow.
- Failure to meet minimum purchase requirements could convert exclusive rights to non-exclusive or terminate the agreement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001570562-26-000079 |
| Document: a78268kex991.htm | 0001570562-26-000079 |
| Document: 0001570562-26-000079-index-headers.html | 0001570562-26-000079 |
| Document: 0001570562-26-000079-index.html | 0001570562-26-000079 |
| Document: 0001570562-26-000079.txt | 0001570562-26-000079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 10w ago | Institutional Cluster | $8.02 $8.16 | ▲ +1.68% | ▲ +1.88% | $7.37 (−8.10%) |
Aug 4, 2026 12w ago | 8-K | $6.12 $6.18 | ▲ +0.98% | ▲ +1.18% | $7.37 (+20.42%) |
Jul 8, 2026 15w ago | 8-K | $6.79 $6.85 | ▲ +0.88% | ▲ +0.04% | $7.37 (+8.54%) |
Jun 15, 2026 19w ago | EFFECT | $6.75 $6.63 | ▼ −1.78% | ▼ −1.18% | $7.37 (+9.19%) |
Jun 5, 2026 20w ago | S-3 | $6.68 $6.70 | ▲ +0.30% | ▲ +0.59% | $7.37 (+10.33%) |
Apr 29, 2026 25w ago | DEFA14A | $5.18 $5.39 | ▲ +4.05% | ▲ +3.03% | $7.37 (+42.28%) |
Mar 17, 2026 32w ago | Insider Cluster | $4.91 $4.83 | ▲ +1.63% | ▲ +0.23% | $7.37 (−50.10%) |
Mar 17, 2026 32w ago | Insider Cluster | $4.91 $4.83 | ▲ +1.63% | ▲ +0.23% | $7.37 (−50.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers